Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice
|
|
- Nathaniel Hutchinson
- 6 years ago
- Views:
Transcription
1 Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice PAUL J. HESKETH St. Elizabeth s Medical Center, Boston, Massachusetts, USA Key Words. Chemotherapy Emesis Emetogenicity ABSTRACT Significant progress has been made in recent years in developing more effective and better tolerated means to prevent nausea and vomiting induced by cancer chemotherapy. The most significant development has been the introduction of a new class of antiemetic agents, the selective antagonists of the type 3 serotonin receptor. With the new antiemetic therapeutic options and their attendant higher costs has come a need to define evidence-based guidelines to assist in their judicious and cost-effective use. A number of predictive factors for antiemetic risk have been defined. Some of these factors relate to the patient INTRODUCTION Nausea and vomiting have consistently ranked high on the list of factors most feared by patients receiving chemotherapy [1, 2]. Inadequately controlled emesis significantly impairs quality of life and increases the risk of patient non-compliance with therapy. Substantial progress has been made over the last decade in developing more effective and better tolerated means to prevent chemotherapy-induced emesis [3]. Several factors have contributed to the therapeutic advances in this area, including new insights into the pathophysiology of emesis, recognition of the value of combination antiemetic therapy, tailoring therapy for both acute emesis ( 24 h after chemotherapy), and delayed emesis (>24 h after chemotherapy) and the development of new antiemetic agents, particularly the selective antagonists of the type 3 serotonin (5-hydroxytyptamine [5-HT 3 ]) receptor. There are currently three 5-HT 3 receptor antagonists (dolasetron, granisetron, and ondansetron) approved for use in the United States. As with other new supportive care agents, however, the availability of new antiemetic agents with their attendant higher acquisition costs compared with older antiemetics has created a need to develop practice population (age, gender, history of ethanol consumption, and prior experience with chemotherapy), and some relate to the treatments administered. Clearly, the most important of all these factors in predicting risk of emesis is the intrinsic emetogenicity of the chemotherapy. Although an ideal emetogenic classification schema for chemotherapy has yet to be realized, recent developments in this area have allowed a more precise estimation of emetogenic risks and have provided antiemetic guideline groups with a useful foundation on which to base their treatment recommendations. The Oncologist 1999;4: guidelines to help ensure their rational and cost-effective use. A reliable method of predicting the risk of emesis following cancer chemotherapy would provide a solid foundation for the development of treatment guidelines for the appropriate use of the 5-HT 3 receptor antagonists and other antiemetics in patients receiving chemotherapy. Over the last 15 years, there has been growing recognition of a number of factors that are important in predicting the risk of emesis following antineoplastic chemotherapy [4-6]. Some of these factors are related to the treatment, including the specific agent(s), chemotherapy dose, route and rate of administration, and antiemetic regimen employed. With many chemotherapy agents, emetic risk is directly proportional to chemotherapy dose. In addition, in general, short i.v. infusions induce more emesis than protracted i.v. infusions or administration by the oral route. Other factors relate to the patient population, including patient age, gender, history of ethanol consumption, and history of prior chemotherapy. Factors associated with decreased risk of emesis include older age, male gender, history of heavy ethanol consumption, and no emesis with prior chemotherapy. Of all these predictive factors, the Correspondence: Paul J. Hesketh, M.D., Division of Hematology/Oncology, St. Elizabeth s Medical Center, 736 Cambridge Street, Boston, Massachusetts 02135, USA. Telephone: ; Fax: ; phesketh@aol.com Accepted for publication March 31, AlphaMed Press /99/$5.00/0 The Oncologist 1999;4:
2 Hesketh 192 intrinsic emetogenicity of the chemotherapy has consistently emerged as the most important. EMETOGENICITY CLASSIFICATION SCHEMAS An ideal emetogenic classification schema would take into account a number of key factors, including: A) derivation from objective data rather than opinion; B) ability to account for the different types of emesis with an ability to predict the likelihood of acute and delayed emesis; C) ability to account for important patient- and treatment-related predictive factors; D) ability to account for the emetogenic potential of combinations, and E) simplicity of use. Several efforts have been made in the past to devise classification schemas for chemotherapy emetogenicity [7-11]. None of these systems have achieved widespread acceptance as a standard schema. Most have significant limitations, including: failure to account for important treatment-related factors, such as chemotherapy dose and rate and route of administration; failure to account for combinations or different patterns of emesis, and reliance on opinion rather than objective data in stratifying chemotherapy agents. In addition, none attempted to account for important patient-related variables. A NEW PROPOSAL FOR DEFINING ACUTE EMETOGENICITY OF CANCER CHEMOTHERAPY Recently, a number of individuals with a longstanding interest in the antiemetic field have proposed a new classification schema for acute emesis [12]. This schema builds upon the system proposed by Lindley et al. [10]. It standardizes chemotherapy rate and route of administration (short i.v. infusion) and patient age (adults), attempts to account for the importance of chemotherapy dose where clinically relevant, includes newer chemotherapy agents, and also proposes an algorithm to predict the emetogenicity of combination regimens. A few oral agents were also classified using customary administration schedules. On the basis of a comprehensive literature search and the consensus of the authors, individual chemotherapy agents were assigned to one of five emetogenic levels. The five levels define the risk of acute emesis in the absence of effective antiemetic prophylaxis. Table 1 lists individual chemotherapy agents by emetogenic level. Since the publication of this schema, a number of additional chemotherapeutic agents have received regulatory approval in the United States and are now incorporated into clinical practice. These include the camptothecin analogs irinotecan and topotecan, and the oral fluoropyrimidine carbamate capecitabine. Review of the clinical experience with these agents to date in phase I and II trials would suggest that capecitabine [13] and topotecan [14, 15] are level 2 agents and that irinotecan is a level 3 agent [16-18]. Table 1. Emetogenic potential of chemotherapy agents Frequency of Level emesis (%)* Agent 5 >90 Carmustine > 250 mg/m 2 Cisplatin 50 mg/m 2 Cyclophosphamide > 1,500 mg/m 2 Dacarbazine Mechlorethamine Streptozocin Carboplatin Carmustine 250 mg/m 2 Cisplatin < 50 mg/m 2 Cyclophosphamide > 750 mg/m 2 1,500 mg/m 2 Cytarabine > 1 g/m 2 Doxorubicin > 60 mg/m 2 Methotrexate > 1,000 mg/m 2 Procarbazine (oral) Cyclophosphamide 750 mg/m 2 Cyclophosphamide (oral) Doxorubicin mg/m 2 Epirubicin 90 mg/m 2 Hexamethylmelamine (oral) Idarubicin Ifosfamide Irinotecan Methotrexate 250-1,000 mg/m 2 Mitoxantrone < 15 mg/m Capecitabine Docetaxel Etoposide 5-Fluorouracil < 1,000 mg/m 2 Gemcitabine Methotrexate > 50 mg/m 2 < 250 mg/m 2 Mitomycin Paclitaxel Topotecan 1 <10 Bleomycin Busulfan Chlorambucil (oral) 2-Chlorodeoxyadenosine Fludarabine Hydroxyurea Methotrexate 50 mg/m 2 L-phenylalanine mustard (oral) Thioguanine (oral) Vinblastine Vincristine Vinorelbine *Proportion of patients who experience emesis in the absence of effective antiemetic prophylaxis. Adapted with permission from [12]. EMETOGENICITY OF CHEMOTHERAPY COMBINATIONS None of the older emetogenic classification schemas adequately accounted for the impact on emetogenicity of administering chemotherapy agents in combination. Recognizing that most chemotherapy agents are administered
3 193 Chemotherapy Emetogenicity Table 2. Algorithm for defining the emetogenicity of combination regimens 1. Identify the most emetogenic agent in the combination. 2. Determine the relative contribution of other agents to the emetogenicity of the combination. When considering other agents, the following rules apply: (A) Level 1 agents do not contribute to the emetogenicity of a given regimen. (B) Adding one or more level 2 agents increases the emetogenicity of the combination by one level greater than the most emetogenic agent in the combination. (C) Adding level 3 or 4 agents increases the emetogenicity of the combination by one level per agent. Adapted with permission from [12]. as part of various combinations and not as single agents, it would be useful in predicting antiemetic risk to have an appropriate means of predicting the effect of combination regimens. Table 2 illustrates an algorithm to help predict the emetogenicity of chemotherapy combinations. The algorithm begins with the identification of the most emetogenic agent in the combination. The relative contribution of other chemotherapy agents to the overall emetogenicity of the combination is then assessed. When considering other agents, the following rules were suggested: A) Level 1 agents do not contribute to the emetogenicity of a given regimen; B) adding one or more level 2 agents increases the emetogenicity of the combination by one level greater than the most emetogenic agent in the combination, and C) adding level 3 or 4 agents increases the emetogenicity of the combination by one level per agent. The algorithm was validated in part using a database of 197 patients assigned to receive a placebo antiemetic as part of four clinical trials comparing the 5-HT 3 receptor antagonist ondansetron with placebo [19-22]. The predicted incidence of emesis with a variety of chemotherapy regimens based upon the algorithm was compared with the actual observed frequency of emesis. For example, 44 patients received a combination of cyclophosphamide (<750 mg/m 2 ) and doxorubicin (20-60 mg/m 2 ) ± vincristine. The predicted emetogenic potential of this combination by the algorithm is level 4 (60%-90% frequency of emesis). Eighty-two percent (36/44) of patients receiving these regimens developed acute emesis when they received a placebo as antiemetic prophylaxis. Similar close correlations were noted between the predicted and observed frequency of emesis with a number of other chemotherapy regimens. A number of potential limitations of this algorithm should be kept in mind, however, The majority of patients from the latter database were women (88%) with breast cancer (79%) receiving primarily cyclophosphamide- and/or anthracycline-based chemotherapy. Few had a history of significant ethanol consumption. Therefore, based upon our knowledge of important patient-related factors, this group has to be considered somewhat high risk for the development of emesis. In addition, the algorithm attempts to predict only acute emesis risk. There is no accounting for the potential for delayed emesis. Clinicians are therefore advised to be cautious in attempting to generalize this algorithm to more diverse populations receiving other chemotherapy regimens. Further studies will be needed to determine the relevance of this algorithm to other patient populations. DEFINING RISK OF DELAYED EMESIS All efforts to date to define emetogenic schemas for chemotherapy agents have concentrated on the potential for emesis within the first 24 h (acute emesis). This is appropriate given the potential severity of uncontrolled acute emesis and the observation that emesis induced by many chemotherapy agents will resolve within 24 h. For a classification schema to be most relevant and serve as a basis for treatment recommendations, however, it must also account for the ability of certain chemotherapy agents to produce emesis beyond the 24-h period following chemotherapy, so-called delayed emesis. Cisplatin is the classic agent by which delayed emesis has been defined. In the absence of appropriate antiemetic prophylaxis, there is an approximate 65%-90% likelihood of delayed emesis following administration of cisplatin [23-25]. A number of other agents, including cyclophosphamide, carboplatin, and doxorubicin, also have the potential to induce delayed emesis. Although the risk of delayed emesis is less than with cisplatin, up to one-third of patients receiving these agents will experience delayed emesis in the absence of delayed antiemetic prophylaxis [26]. RELEVANCE OF CHEMOTHERAPY EMETOGENICITY TO CURRENT ANTIEMETIC USE AND CLINICAL RESEARCH At present, no comprehensive emetogenic classification schema that fulfills all the criteria of the ideal schema has been devised. However, given the pressing need to define rational evidence-based guidelines to help guide antiemetic use, the recently proposed schema [12] has been used as a framework for such recommendations. The National Comprehensive Cancer Network (NCCN) has used this classification schema as the basis for their recently released antiemetic guidelines [27]. For acute antiemetic prophylaxis in patients receiving chemotherapy with level 3-5 emetogenic potential, they recommended the use of an oral 5-HT 3 receptor antagonist
4 Hesketh 194 National Comprehensive Cancer Network (NCCN) Antiemesis Practice Guidelines Acute Primary treatment (Day 1) emetogenic potential PO tolerated:* Granisetron, 2 mg PO qd or 1 mg bid or Ondansetron, 8 mg PO bid (for high: category 2) or Dolasetron, 100 mg PO qd (for high: category 2) High to + Dexamethasone, mg PO moderate ± Lorazepam, mg PO (levels ) Start before chemotherapy Repeat daily for fractionated doses of chemotherapy PO not tolerated:* Ondansetron, 8 mg (maximum, 32 mg) i.v. or Granisetron, 10 µg/kg (maximum, 1 mg ) i.v. or Dolasetron, 1.8 mg/kg i.v. or 100 mg i.v. + Dexamethasone, mg i.v. ± Lorazepam, mg i.v. Categories of acceptability for guideline recommendations Category 1: Recommendations that are uncontested and generally accepted by all authorities in that particular cancer. Category 2: Recommendations that are somewhat controversial. Category 3: Recommendations that caused real disagreements among members of the NCCN panel. Figure 1. Recommended antiemetic prophylaxis for patients receiving chemotherapy with level 3-5 acute emetogenic potential. *Order of listed antiemetics does not reflect preference. Reproduced with permission from [27]. The NCCN guidelines are a statement of consensus of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN guideline is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient s care or treatment. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. combined with oral dexamethasone prior to chemotherapy (Fig. 1). For patients receiving level 2 chemotherapy, they recommended an oral dose of a dopaminergic antagonist or oral dexamethasone alone. For level 1 chemotherapy, no routine antiemetic prophylaxis was recommended (Fig. 2). Recognizing the potential of certain agents to induce delayed emesis, they also offered specific recommendations in this setting as well (Fig. 3). A simple-to-use, comprehensive emetogenic classification schema would also have potential relevance to antiemetic research. Efforts to develop additional useful antiemetic agents to address unmet needs (delayed emesis, high-dose chemotherapy, and multi-day chemotherapy) are continuing. Cisplatin has traditionally served as the gold standard emetogenic challenge in new agent development. As cisplatin use declines, however, the ability to evaluate new agents in a National Comprehensive Cancer Network (NCCN) Antiemesis Practice Guidelines Acute Primary treatment (Day 1) emetogenic potential PO tolerated:* Dexamethasone, mg PO or Prochlorperazine, 10 mg PO q4-6h or 15mg spansule PO q8-12h Low or Thiethylperazine, 10 mg PO q4-6h (level 2) or Metoclopramide, 20 mg PO q4-6h + diphenhydramine, 25 mg PO q4-6h PRN ± Lorazepam, mg PO q4-6h Start 30 min before chemotherapy Repeat daily for fractionated doses of chemotherapy Unlikely (level 1) PO not tolerated:* Dexamethasone, 20 mg i.v. or Prochlorperazine, 10 mg i.v. q4-6h or Metoclopramide, 0.5 mg/kg i.v. q3-4h + diphenhydramine, mg i.v. PRN ± Lorazepam, mg i.v., q4-6h No prophylactic treatment Figure 2. Recommended antiemetic prophylaxis for patients receiving chemotherapy with level 1-2 acute emetogenic potential. *Order of listed antiemetics does not reflect preference. Reproduced with permission from [27]. The NCCN guidelines are a statement of consensus of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN guideline is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient s care or treatment. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. timely manner has become an increasing challenge. An emetogenic classification schema that allows more precision in defining emetic risk, particularly in high-risk patient categories, could potentially facilitate new antiemetic agent development. SUMMARY Substantial progress has been realized over the last 15 years in predicting the risk of emesis following cancer chemotherapy. Of the known predictive factors, the intrinsic emetogenicity and pattern of emesis have emerged as the most clinically relevant. A better understanding of the latter factors has allowed the development of rational guidelines to help assist the clinician in using antiemetic agents in the most rational and cost effective manner possible. Efforts should continue to develop more comprehensive emetogenic schemas that attempt to take into account all of the known patient- and treatment-related factors.
5 195 Chemotherapy Emetogenicity Figure 3. Recommended antiemetic prophylaxis for patients receiving chemotherapy with delayed emetogenic potential. *Order of listed antiemetics does not reflect preference. Reproduced with permission from [27]. Cisplatin, 50 mg/m 2 The NCCN guidelines are a statement of consensus of its authors regard- Cyclophosphamide, Carboplatin, 300 mg/m 2 ing their views of currently accepted 600-1,000 mg/m 2 approaches to treatment. Any clinician Doxorubicin, 50 mg/m 2 seeking to apply or consult any NCCN guideline is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient s care or treatment. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. REFERENCES 1 Coates A, Abraham S, Kaye SB et al. On the receiving end: patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19: Griffin AM, Butow PN, Coates AS et al. On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in Ann Oncol 1996;7: Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med 1993;329: D Acquisto R, Tyson LB, Gralla RJ et al. The influence of a chronic high alcohol intake on chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol 1986;5: Hesketh PJ, Plagge P, Bryson JC. Single-dose ondansetron for prevention of acute cisplatin-induced emesis: analysis of efficacy and prognostic factors. In: Bianchi AL, Grelot L, Miller AD et al., eds. Mechanisms and Control of Emesis. London: Libbey, 1992: Tonato M, Roila F, Del Favero A. Methodology of antiemetic trials: a review. Ann Oncol 1991;2: Laszlo J. Treatment of nausea and vomiting caused by cancer chemotherapy. Cancer Treat Rev 1982;9: Strum SB, McDermed JE, Pileggi J et al. Intravenous metoclopramide: prevention of chemotherapy-induced nausea and vomiting. Cancer 1984;53: Craig JB, Powell BL. Review: the management of nausea and vomiting in clinical oncology. Am J Med Sci 1987;293: Lindley CM, Bernard S, Fields SM. Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol 1989;7: Aapro MS. Methodological issues in antiemetic studies. Invest New Drugs 1993;11: National Comprehensive Cancer Network (NCCN) Antiemesis Practice Guidelines Delayed Prevention (Days 2-5) emetogenic potential *Metoclopramide, 0.5 mg/kg PO qid 4 days + Dexamethasone, 8 mg PO bid 2 days, then 4 mg bid 2 days (category 2 for cyclophosphamide or doxorubicin) or Ondansetron, 8 mg PO bid 3 days ± Dexamethasone, 8 mg PO bid 3 days (category 2 for cyclophosphamide or doxorubicin) or Dexamethasone, 8 mg PO bid 2 days, then 4 mg bid 2 days ± Lorazepam, mg PO q6h ± Diphenhydramine, mg PO q6h 12 Hesketh PJ, Kris MG, Grunberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15: Blum JL, Jones SE, Buzdar AU et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17: Lynch TJ, Kalish L, Strauss G et al. Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 1994;12: Schiller JH, Kim K, Hutson P et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 1996;14: Armand JP, Extra YM, Catimel G et al. Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies. Ann Oncol 1996;7: Merrouche Y, Extra JM, Abigerges D et al. High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study. J Clin Oncol 1997;15: Rothenberg ML, Cox JV, DeVore RF et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999;85: Cubeddu LX, Hoffman IS, Fuenmayor NT et al. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens. J Clin Oncol 1990;8: Beck TM, Ciociola AA, Jones SE et al. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 1993;118:
6 Hesketh Cubeddu LX, Pendergrass K, Ryan T et al. Efficacy of oral ondansetron, a selective antagonist of 5-HT 3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Am J Clin Oncol 1994;17: DiBenedetto J Jr, Cubeddu LX, Ryan T et al. Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Clin Ther 1995;17: Kris MG, Gralla RJ, Clark RA et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985;3: Gandara DR, Harvey WH, Monaghan GG et al. The delayedemesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. Semin Oncol 1992;19: Navari RM, Madajewicz S, Anderson N et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol 1995;13: Tavorath R, Hesketh PJ. Drug treatment of chemotherapyinduced delayed emesis. Drugs 1996;52: National Comprehensive Cancer Network Antiemesis Practice Guidelines, Vol. 2. NCCN proceedings. Oncology 1997;11:57-89.
MASCC Guidelines for Antiemetic control: An update
MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,
More informationGUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,
More informationGuideline Update on Antiemetics
Guideline Update on Antiemetics Clinical Practice Guideline Special Announcements Please check www.asco.org/guidelines/antiemetics for current FDA alert(s) and safety announcement(s) on antiemetics 2 Introduction
More informationGuidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients
Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For
More informationWest of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial
More informationClinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:
Clinical Policy: (Anzemet) Reference Number: ERX.NPA.83 Effective Date: 09.01.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationGuidelines for the Use of Anti-Emetics with Chemotherapy
Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting
More informationClinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:
Clinical Policy: (Cesamet) Reference Number: ERX.NPA.35 Effective Date: 09.01.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationClinical Policy: Ondansetron (Zuplenz) Reference Number: CP.PMN.45 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Zuplenz) Reference Number: CP.PMN.45 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Anzemet) Reference Number: CP.PMN.141 Effective Date: 09.01.06 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationExhibit B United States Patent Application 20020012663 Kind Code A1 Waksal, Harlan W. January 31, 2002 Treatment of refractory human tumors with epidermal growth factor receptor antagonists Abstract A
More informationSubject: Fosnetupitant-Palonosetron (Akynzeo) IV
09-J3000-01 Original Effective Date: 06/15/18 Reviewed: 05/09/18 Revised: 01/01/19 Subject: Fosnetupitant-Palonosetron (Akynzeo) IV THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More informationManagements of Chemotherpay Induded Nausea and Vomiting
REVIEW ARTICLE Managements of Chemotherpay Induded Nausea and Vomiting Department of Surgery, The Catholic University of Korea Sung Geun Kim 23 24 Sung Geun Kim Korean Journal of Clinical Oncology Summer
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Cesamet) Reference Number: CP.PMN.160 Effective Date: 11.16.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationPrevention and Management of chemo-and radiotherapy-induced nausea and vomiting
Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University of Heidelberg
More informationNorthern Cancer Alliance
Northern Cancer Alliance Anti-emetic Guidelines for Chemotherapy Induced Nausea and Vomiting (CINV) Adult Oncology & Haematology Document Control Document Title: Antiemetic Guidelines for CINV NESCN v2.2
More informationSubject: Palonosetron Hydrochloride (Aloxi )
09-J0000-87 Original Effective Date: 02/15/09 Reviewed: 07/09/14 Revised: 03/15/18 Subject: Palonosetron Hydrochloride (Aloxi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationStudent Project PRACTICE-BASED RESEARCH
Pharmacist-Driven Management of Chemotherapy Induced Nausea and Vomiting in Hospitalized Adult Oncology Patients. A Retrospective Comparative Study Ramy Elshaboury, PharmD 1 and Kathleen Green, PharmD,
More informationTRANSPARENCY COMMITTEE OPINION. 31 January Date of marketing authorisation: 22 March 2005 (centralised marketing authorisation)
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 31 January 2007 ALOXI 250 µg solution for injection B/1 CIP 375,482-8 Applicant: THERABEL LUCIEN PHARMA palonosetron
More informationChemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines
North of England Cancer Network Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines Adult Oncology & Haematology Quality and safety for every patient every time For more information
More informationEmetogenicity level 1. Emetogenicity level 2
Emetogenicity level 1 15 mins Pre-Chemo Maxalon 10mg po During chemo and Post Chemo 3 days Maxalon10mg po 8 hourly Increase Maxalon 20mg po 8 hourly Change to Cyclizine 50mg po 8 hourly 3 days If nausea
More informationSystemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients
Systemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients Pathway of Care Kent & Medway Cancer Collaborative Publication date June 2018
More informationAPPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer
APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer 5850/5980 University Avenue, PO Box 9700, Halifax, N.S. B3K 6R8 PEDIATRIC HEMATOLOGY/ONCOLOGY
More informationPrevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference
Annals of Oncology 17: 20 28, 2006 doi:10.1093/annonc/mdj078 Published online 28 November 2005 Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic
More informationSCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders
1.0 Introduction The (SCI) is a not-for-profit collaboration between the Hospital for Sick Children (SickKids), Toronto, Canada, and seven Caribbean health care institutions across six countries that strive
More informationPrevention of chemotherapy induced nausea and vomiting in pediatric cancer patients
REVIEW ARTICLE Prevention of chemotherapy induced nausea and vomiting in pediatric cancer patients Shubham Roy 1, Rashi Kulshrestha 2, Abhishek Shankar 3, Goura Kishor Rath 4, Vipin Kharade 4 1 Department
More informationPing-Tsung Chen, MD; Chuang-Chi Liaw, MD
Original Article 167 Intravenous Ondansetron plus Intravenous Dexamethasone with Different Ondansetron Dosing Schedules during Multiple Cycles of Cisplatin-based Chemotherapy Ping-Tsung Chen, MD; Chuang-Chi
More informationA Comparison of Oral Ondansetron and Intravenous Granisetron for the Prevention of Nausea and Emesis Associated with Cisplatin-Based Chemotherapy
A Comparison of Oral Ondansetron and Intravenous Granisetron for the Prevention of Nausea and Emesis Associated with Cisplatin-Based Chemotherapy JESSE I. SPECTOR, a ERIC P. LESTER, b ERIC M. CHEVLEN,
More informationSupportive care session 1:
Board review in oncology pharmacy 2013 Managing Disease or Treatment Related Complication Supportive care session 1: Chemotherapy induced-nausea and vomiting Suthan Chanthawong, B. Pharm, RPh. Objectives
More informationJob title: Consultant Pharmacist/Advanced Practice Pharmacist
Title : Guidelines for the Use of Antiemetics Purpose: To provide trust-wide guidance on the safe and effective use of antiemetics for the prevention and treatment of chemotherapy and radiotherapy induced
More informationDelayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only)
Support Care Cancer (2011) 19 (Suppl 1):S57 S62 DOI 10.1007/s00520-010-1039-y SPECIAL ARTICLE Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only) Fausto Roila & David
More informationGuideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients POGO Antineoplastic Induced Nausea and Vomiting Guideline Development Panel: L.
More informationClinical Policy: Aprepitant (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17
Clinical Policy: (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationCorporate Medical Policy
Antiemetic Injection Therapy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: antiemetic_injection_therapy 5/2015 3/2017 3/2018 3/2017 Description of Procedure
More informationPrevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting
Prevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University
More informationCommittee Approval Date: December 12, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru378 Topic: Akynzeo, netupitant/palonosetron Date of Origin: December 12, 2014 Committee Approval Date: December 12, 2014 Next Review Date: July 2015 Effective Date:
More informationMOLECULAR AND CLINICAL ONCOLOGY 2: , 2014
MOLECULAR AND CLINICAL ONCOLOGY 2: 375-379, 2014 Palonosetron exhibits higher total control rate compared to first generation serotonin antagonists and improves appetite in delayed phase chemotherapy induced
More informationSubject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi )
09-J2000-60 Original Effective Date: 06/15/16 Reviewed: 04/11/18 Revised: 01/01/19 Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT
More informationPERUGIA INTERNATIONAL CANCER CONFERENCE VII MULTINATIONAL ASSOCIATION FOR SUPPORTIVE CARE IN CANCER
June 2004 PERUGIA INTERNATIONAL CANCER CONFERENCE VII MULTINATIONAL ASSOCIATION FOR SUPPORTIVE CARE IN CANCER CONSENSUS CONFERENCE ON ANTIEMETIC THERAPY PERUGIA, March 29-31, 2004 DELAYED EMESIS WORKING
More informationANTIEMETIC GUIDELINES: MASCC/ESMO
Open Issues for CINV Do we reliably measure that? Do we control nausea optimally? Are guidelines useful for oral therapies related nausea and vomiting? Breakthrough and refractory nausea and vomiting:
More informationOral Granisetron for the Prevention of Acute Late Onset Nausea and Vomiting in Patients Treated with Moderately Emetogenic Chemotherapy
Oral Granisetron for the Prevention of Acute Late Onset Nausea and Vomiting in Patients Treated with Moderately Emetogenic Chemotherapy CARL J. FRIEDMAN, a HOWARD A. BURRIS III, b KAREN YOCOM, a LINDA
More informationMEDICAL NECESSITY GUIDELINE
PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationATTUALITÀ NEL CONTROLLO DELL EMESI
ATTUALITÀ NEL CONTROLLO DELL EMESI Dr Claudio Lotesoriere Dipartimento di Oncoematologia S.C. di Oncologia Medica P.O. San G. Moscati TARANTO email oncologia.taranto@gmail.com Types of CINV: Definitions
More informationCurrent and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives
Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Susan Urba, M.D. University of Michigan Comprehensive Cancer Center Objectives Mechanisms of
More informationChemotherapy Induced Nausea and Vomiting
Chemotherapy Induced Nausea and Vomiting Aminah Jatoi, M.D. Professor of Oncology Mayo Clinic Rochester, Minnesota April 27, 2017 clinical and biologic fundamentals of chemotherapy induced nausea and vomiting
More informationComparing Different Antiemetic Regimens for Chemotherapy Induced Nausea and Vomiting
Comparing Different Antiemetic Regimens for Chemotherapy Induced Nausea and Vomiting Sayantani Ghosh, Saugat Dey Corresponding author: Sayantani Ghosh (ghoshsayantani@rediffmail.com) Correspondence concerning
More informationGastrointestinal Alterations
Gastrointestinal Alterations Nancy Thompson, RN, MS, AOCNS Swedish Cancer Institute Nausea & Vomiting Mucositis Taste Alterations Anorexia / Cachexia GI Alterations The Chinese do not draw any distinction
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Kytril, Sancuso, Sustol) Reference Number: CP.PMN.74 Effective Date: 11.01.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important
More informationManaging Adverse Events in the Cancer Patient. Learning Objectives. Chemotherapy-Induced Nausea/Vomiting
Managing Adverse Events in the Cancer Patient Lisa A Thompson, PharmD, BCOP Assistant Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Learning Objectives Describe
More informationDrug: Aprepitant (Emend ) Date of Review: 4/01/10
CAMBRIDGESHIRE JOINT PRESCRIBING GROUP Business Case Evaluation and Recommendation Document Drug: Aprepitant (Emend ) Date of Review: 4/01/10 Business Case Decision and date: DOUBLE RED, 20 January 2010
More informationAntiemesis. NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version Continue
Table of Contents Clinical in Oncology Version 2.2010 Continue www.nccn.org Version 2.2010, 04/07/2010 2010 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration
More informationDescription The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet )
Clinical Policy: Nabilone (Cesamet), Dronabinol (Marinol, Syndros) Reference Number: CP.CPA.242 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important
More informationClinical Tools and Resources for Self-Study and Patient Education
Clinical Tools and Resources for Self-Study and Patient Education CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING CLINICIAN'S RESOURCE GUIDE The clinical tools and resources contained herein are provided as educational
More informationAntiemetic Prophylaxis with Ondansetron and Methylprednisolone vs Metoclopramide and Methylprednisolone in Mild and Moderately Emetogenic Chemotherapy
218 Journal of Pain and Symptom Management Vol. 18 No. 3 September 1999 Original Article Antiemetic Prophylaxis with Ondansetron and Methylprednisolone vs Metoclopramide and Methylprednisolone in Mild
More informationManagement of Nausea and Vomiting
June 01, 2015 By Rudolph M. Navari, MD, PhD, FACP [1] Although marked progress in controlling chemotherapy-induced emesis has occurred over the past 25 years, nausea and vomiting remain among the most
More informationUpdates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017
Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017 MELISSA C. MACKEY, PHARMD, BCPS, BCOP ONCOLOGY CLINICAL PHARMACIST DUKE UNIVERSITY HOSPITAL AUGUST 5, 2017 Objectives Review risk factors
More informationTrust Guideline for Prevention and Control of Chemotherapy and Radiotherapy Induced Nausea and Vomiting in Adults
A Clinical Guideline For Use in: Organisation-wide By: For: Key words: Name of document author: Job title of document author: Name of document author s Line Manager: Job title of author s Line Manager:
More informationclinical practice guidelines
clinical practice guidelines Annals of Oncology 21 (Supplement 5): v232 v243, 2010 doi:10.1093/annonc/mdq194 Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced
More informationOrganizing and Overall Meeting Chairs: Richard J. Gralla, MD Fausto Roila, MD Maurizio Tonato, MD
PERUGIA INTERNATIONAL CANCER CONFERENCE VII MULTINATIONAL ASSOCIATION FOR SUPPORTIVE CARE IN CANCER CONSENSUS CONFERENCE ON ANTIEMETIC THERAPY PERUGIA, March 29-31, 2004 Organizing and Overall Meeting
More informationDrug Name: Aprepitant (Emend ) Manufacturer: Merck & Co., Inc.
Drug Name: Aprepitant (Emend ) Manufacturer: Merck & Co., Inc. Pharmacology: Aprepitant (previously known as MK-0839 and L-754030) is a new molecular entity that is the first in a new therapeutic class,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.223 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationWhy Patients Experience Nausea and Vomiting and What to Do About It
Why Patients Experience Nausea and Vomiting and What to Do About It Rebecca Clark-Snow, RN, BSN, OCN The University of Kansas Cancer Center Westwood, Kansas Multiple Roles for Supportive Care in Cancer
More informationAntiemetics: Guidelines, Interactions and more.
Antiemetics: Guidelines, Interactions and more. Chemotherapy-induced side effects -the patient s view Loss of hair The thought of coming for chemo Affects family/partner Affects work/home duties Jude Lees
More informationUsing a Simple Diary for Management of Nausea and Vomiting During Chemotherapy
Using a Simple Diary for Management of Nausea and Vomiting During Chemotherapy Problem identification Nausea and vomiting (N&V) are frequent complications following chemotherapy, even when taking 5-HT3
More informationChemotherapy induced emesis: Are we doing are best? David Warr University of Toronto
Chemotherapy induced emesis: Are we doing are best? David Warr University of Toronto david.warr@uhn.on.ca Conflict of interest Merck: speakers bureau and consultant Eisai: consultant Outline What is the
More informationThe influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting
Journal of BUON 12: 245-252, 2007 2007 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE The influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting T. Sarcev
More informationSURVEY SUL CONFLITTO DI INTERESSE IN ONCOLOGIA PROMOSSO DAL CIPOMO 1-31 MARZO. PARTECIPATE TUTTI nicsonet.it
SURVEY SUL CONFLITTO DI INTERESSE IN ONCOLOGIA PROMOSSO DAL CIPOMO 1-31 MARZO PARTECIPATE TUTTI www.cipomo.it; nicsonet.it LINEE GUIDA AIOM: LA TERAPIA ANTIEMETICA Fausto Roila S.C. Oncologia Medica, Terni
More informationDRUG EXTRAVASATION. Vesicants. Irritants
DRUG EXTRAVASATION Vesicants Irritants Vesicants Antineoplastic drugs Amsacrine Dactinomycin Daunorubicin Docetaxel (rare) Doxorubicin Epirubicin Idarubicin Mechlorethamine Mitomycin Oxaliplatin (rare)
More informationECN Protocol Book. Antiemetic Guidelines for Adult Patients Receiving Chemotherapy and Radiotherapy
ECN Protocol Book Antiemetic Guidelines f Adult Patients Receiving Chemotherapy and Radiotherapy Name of person presenting document: Reason f document development: Names of development team: Specify groups
More informationRichard J. Gralla, MD Medical Director Quality of Life Research Associates New York, NY
Oncology Consultations Improving the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) A CE-Certified Activity Featuring Consultations With Supported by an educational grant from Eisai. Dannemiller
More informationNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Antiemesis. Version NCCN.org. Continue
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2011 NCCN.org Continue Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that
More informationUpdate on antiemetics, what is new and future directions. Karin Jordan University of Halle
Update on antiemetics, what is new and future directions Karin Jordan University of Halle History of Antiemetics Controlling Chemotherapy-Induced EMESIS: Progress Over The Past 30 Years: Efficacy 5-Day
More informationRolapitant (Varubi) A Substance P/Neurokinin-1 Receptor Antagonist for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Rolapitant (Varubi) A Substance P/Neurokinin-1 Receptor Antagonist for the Prevention of Chemotherapy-Induced Nausea and Vomiting Tamara Goldberg, PharmD, BCPS; Brooke Fidler, PharmD; and Stephanie Cardinale,
More informationVision of the Future: Capecitabine
Vision of the Future: Capecitabine CHRIS TWELVES Cancer Research Campaign Department of Medical Oncology, University of Glasgow, and Beatson Oncology Centre, Glasgow, United Kingdom Key Words. Capecitabine
More informationComparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens
569 Ivyspring International Publisher Research Paper Journal of Cancer 2016; 7(5): 569-575. doi: 10.7150/jca.13637 Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk
More informationAntiemetics in chemotherapy
Antiemetics in chemotherapy Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Date of submission Date
More informationGUIDELINE FOR THE MANAGEMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING.
Page 1 of 20 Guideline for the management of chemotherapy-induced nausea and vomiting, v2.1.1 GUIDELINE FOR THE MANAGEMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING. Version: 2.1.0 Ratified by: Date
More informationChemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study
Support Care Cancer (2012) 20:107 117 DOI 10.1007/s00520-010-1073-9 ORIGINAL ARTICLE Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study Doranne L. Hilarius
More informationPediatric Trials 23/04/2018. Disclosures. Nausea and Vomiting Control in Adults and Children: Mind the Gap! Learning Objectives
Nausea and Vomiting Control in Adults and Children: Mind the Gap! Disclosures No relevant conflicts of interest Lee Dupuis, RPh, PhD May 5, 2018 2 Learning Objectives At the end of this presentation, attendees
More informationChemotherapy-Related Nausea and Vomiting and Treatment-Related Nausea and Vomiting
CHAPTER 12 Chemotherapy-Related Nausea and Vomiting and Treatment-Related Nausea and Vomiting Elizabeth Blanchard T he ability of chemotherapy to cause nausea and vomiting is legendary and remains a widespread
More informationOncologist. The. Chemotherapy-Induced Nausea and Vomiting: The Importance of Acute Antiemetic Control FREDERICK M.
The Oncologist Chemotherapy-Induced Nausea and Vomiting: The Importance of Acute Antiemetic Control FREDERICK M. SCHNELL Central Georgia Hematology and Oncology Associates, Macon, Georgia, USA Key Words.
More informationReview Article Prevention of Nausea and Vomiting in Patients Undergoing Oral Anticancer Therapies for Solid Tumors
Hindawi Publishing Corporation BioMed Research International Volume 2015, Article ID 309601, 7 pages http://dx.doi.org/10.1155/2015/309601 Review Article Prevention of Nausea and Vomiting in Patients Undergoing
More informationPatient-Centered Management of Chemotherapy-Induced Nausea and Vomiting
Clear and accurate communication between patients and health care teams is the key to successfully controlling chemotherapy-induced nausea and vomiting. Roseate Spoonbill_2005. Photograph courtesy of Henry
More informationManagement of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients
Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients By Zahra Shaghaghi, Pharm-D, BCOP, PhC Prepared for 2018 NMSHP Balloon Fiesta Symposium Goals and Objectives: Describe
More informationManagement of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients
Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients By Zahra Shaghaghi, Pharm-D, BCOP, PhC Prepared for 2018 NMSHP Balloon Fiesta Symposium 1 Goals and Objectives: Describe
More informationPrevention CINV (highly emetogenic) Prevention PONV
Reviews/Evaluations 5-Hydroxytryptamine3 (5-HT3) Receptor Antagonists Generic Name Brand Name Manufacturer Dolasetron Anzemet Aventis Granisetron Kytril Roche Ondansetron Zofran GlaxoSmithKline I. FDA
More informationAntiemesis. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version NCCN.org. Continue
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2015 NCCN.org Continue Version 1.2015, 04/01/15 National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN
More informationReview Article Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting
Hindawi Publishing Corporation BioMed Research International Volume 2015, Article ID 595894, 6 pages http://dx.doi.org/10.1155/2015/595894 Review Article Treatment of Breakthrough and Refractory Chemotherapy-Induced
More informationChemotherapy-Induced Nausea and Vomiting: Strategies for Achieving Optimal Control
Chemotherapy-Induced Nausea and Vomiting Strategies for Achieving Learning Objectives Describe the challenges of assessing nausea in patients undergoing chemotherapy and the impact of nausea and also vomiting
More informationThe incidence of chemotherapy-induced emesis is difficult to determine, because the cause is likely to be multifactorial and include factors such as
Pediatric Hematology and Oncology, 21: 227 235, 2004 Copyright C Taylor & Francis Inc. ISSN: 0888-0018 print / 1521-0669 online DOI: 10.1080/08880010490427351 SINGLE-DOSE ORAL GRANISETRON VERSUS MULTIDOSE
More informationChemotherapy-induced nausea and vomiting (CINV)
At a Glance Practical Implications e54 Author Information e57 Full text and PDF 5-HT3 Receptor Antagonist Effects in Cancer Patients With Multiple Risk Factors Original Research Claudio Faria, PharmD,
More informationPublished Ahead of Print on September 26, 2011 as /JCO J Clin Oncol by American Society of Clinical Oncology
Published Ahead of Print on September 26, 2011 as 10.1200/JCO.2010.34.4614 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2010.34.4614 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C
More information9/21/2016. Disclosures. Updates in the Management of Chemotherapy induced Nausea and Vomiting (CINV) Introduction. Objectives.
Updates in the Management of Chemotherapy induced Nausea and Vomiting (CINV) Diwura Owolabi, Pharm.D, BCOP Clinical Pharmacy Specialist, Blood and Marrow Transplantation Methodist University Hospital,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Zofran, Zuplenz) Reference Number: CP.CPA.173 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this
More informationTo help doctors give their patients the best possible care, the American
Patient Information Resources from ASCO What to Know ASCO s Guideline on Preventing Vomiting Caused by Cancer Treatment SEPTEMBER 2011 KEY MESSAGES The risk of nausea and vomiting depends on the specific
More informationPREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN ELDERLY CANCER PATIENTS JØRN HERRSTEDT, M.D. COPENHAGEN UNIVERSITY HOSPITAL HERLEV, DENMARK
PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN ELDERLY CANCER PATIENTS JØRN HERRSTEDT, M.D. COPENHAGEN UNIVERSITY HOSPITAL HERLEV, DENMARK HISTORY OF ANTIEMETICS 1979 A corticosteroid is superior
More information